Clinical Trial

Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes

Study acronym: DHB
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2025 (before its estimated January 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if Dihydroberberine (DHB) supplementation affects adults with pre-diabetes. The main questions it aims to answer are: Does DHB supplementation increase the concentration of GLP-1 in the blood? Does DHB supplementation affect appetite, mood, and energy levels? Does DHB supplementation affect body weight, blood sugar control and insulin? Researchers will compare DHB supplementation to a placebo (a look-alike substance that contains no drug) to see if DHB has any effect. Participants will: Take DHB or a placebo every day for 6 weeks. Participate in tests to measure GLP-1 levels, blood glucose, insulin and other markers. Have their continuous blood sugar profiles (with CGMs) monitored to see how much time their blood sugar spends in a healthy range. Rate their appetite, mood, and energy levels using a visual analog scale.
Trial Details
NCT Number NCT07210684
Lead Sponsor Nanjing Nutrabuilding Bio-tech Co., Ltd.
Collaborators: Biofortis, Merieux NutriSciences
Conditions Prediabetes
Enrollment 54 participants
Start Date 2025-08-06
Primary Completion 2026-01-15 (estimated)
Study Completion 2026-03-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-07